Love Health

French National Scientific Research Center, 26, issued a statement that the agency found that a peptide of lupus erythematosus has a good effect, and it has been the success of people and animals were tested. Related results published in the latest issue of the United States, “arthritis and rheumatism,” the magazine’s electronic edition.

French National Scientific Research Center, said that lupus erythematosus is a chronic immune system diseases can lead to the body’s immune system to identify the loss of capacity, even as the organization’s own targets.The disease of the body’s organs will have a number of hazards, and its symptoms mainly joint pain, fever, rash and hair, to young and middle-aged patients are more women than men. The disease is no specific drug.

French National Scientific Research Center for Molecular and Cell Biology Institute Na Mile Silvia led the research team found that in 2001, called a “P140″ of the peptide, it can resume normal function of the immune system. The team used this peptide treatment of mice suffering from lupus erythematosus, the result has been obvious effect: the sick mice significantly extend the life span is even close to the normal life span of mice, in addition, they also ease arthritis.

Subsequently, the research team at a pharmaceutical company with the financial support of clinical trials conducted. Bulgaria in the two hospitals selected 20 patients with lupus, per patient 3rd that voluntarily accept polypeptide of subcutaneous injection, each separated by 15 days time. The test results are encouraging: the lupus activity index decreased very significantly.

The researchers believe that the animal and human test full proof of “P140″ effectiveness, and lupus erythematosus, compared to the existing therapy, it’s a small side-effects. The team is currently under way for a new round of clinical trials, hoping to develop specific drug treatment for lupus.